Fig. 1
From: GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
GD2-BsAb and HER2-BsAb exerted strong cytotoxicity against osteosarcoma. a Antibody-dependent T cell-mediated cytotoxicity (ADTC) was analyzed by 51Cr release assay using activated T cells (ET ratio, 10 to 1) at decreasing concentrations of BsAb in an osteosarcoma cell line panel. Cytotoxicity was compared to control BsAb with T cells and each BsAb alone. b In vivo anti-tumor activity of GD2-BsAb and HER2-BsAb against osteosarcoma. c Immunohistochemical (IHC) staining of tumor-infiltrating lymphocytes. Tumors were harvested on day 30 post-treatment and stained with anti-human CD3 antibody (× 200). d IHC staining of tumors by anti-human CD4 and anti-human CD8 antibody (× 200) following treatment with iv PBMC and iv GD2-BsAb